Key result
While aggressive lipid-lowering strategies reduce cardiovascular risk, excessively low LDL-C levels and statin therapy may be associated with unintended consequences such as increased risks of glaucoma, intracranial hemorrhage, and new-onset diabetes.
Why the study?
Current guidelines emphasize aggressive LDL-C lowering, but emerging evidence suggests excessively low LDL-C and statin therapy may have unintended health consequences, highlighting the need to reassess the lower is better paradigm.
Do intensive lipid-lowering therapy and very low LDL-C levels increase the risk of glaucoma, intracranial hemorrhage, and new-onset diabetes?
Do intensive lipid-lowering therapy and very low LDL-C levels increase the risk of glaucoma, intracranial hemorrhage, and new-onset diabetes?
Answers are grounded in this paper and cite their sources.
This review highlights emerging evidence that excessively low LDL-C levels and intensive statin therapy may increase the risk of glaucoma, intracranial hemorrhage, and new-onset diabetes, challenging the 'lower is better' paradigm.
Atherosclerotic cardiovascular disease remains a major global health burden. Current guidelines emphasize aggressive lipid-lowering strategies, particularly those that reduce low-density lipoprotein cholesterol (LDL-C) levels. While effective in lowering cardiovascular risk, excessively low LDL-C may have unintended health consequences. LDL-C plays a critical physiological role in cellular structure and hormone synthesis. Emerging evidence links low LDL-C and high HDL-C with increased glaucoma risk. Statins, which are commonly used to lower LDL-C, may further increase this risk, raising concerns for patients with coronary artery disease. Low LDL-C has also been associated with gestational diabetes and intracranial hemorrhage, while statin therapy may contribute to new-onset diabetes mellitus. These findings highlight the need to reassess the "lower is better" paradigm. A patient-centered, risk-based approach to statin therapy is recommended. Large-scale randomized controlled trials are urgently needed to establish safe lipid thresholds and optimize therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Cüre et al. (2025) conducted an editorial in Atherosclerotic cardiovascular disease and dyslipidemia. Intensive lipid-lowering therapy and low LDL-C was evaluated. While aggressive lipid-lowering strategies reduce cardiovascular risk, excessively low LDL-C levels and statin therapy may be associated with unintended consequences such as increased risks of glaucoma, intracranial hemorrhage, and new-onset diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: